IL-5 inhibiting 6-azauracil derivatives

Details IL-5 inhibiting 6-azauracil derivatives IL-5 inhibiting 6-azauracil derivatives

2005-03-15

2005-03-15

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S227800, C544S182000, C544S112000, C544S060000

Reexamination Certificate

active

06867207

ABSTRACT:
The present invention is concerned with the compounds of formulathe N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, p and q are 0, 1, 2, 3 or 4 and q is also 5; X is O, S, NR3or a direct bond; R1is hydrogen, hydroxy, halo, optionally substituted amino, optionally substituted C1-6alkyl, C1-6alkyloxy, C3-7cycloalkyl or aryl; R2is aryl, Het1, C3-7cycloalkyl, optionally substituted C1-6alkyl; and if X is O, S or NR3, then R2may also be a carbonyl or thiocarbonyl linked substituent; R3is hydrogen or C1-4alkyl; R4and R5independently are optionally substituted C1-6alkyl, halo, hydroxy, mercapto, C1-6alkyloxy, C1-6akylthio, C1-6alkylcarbonyloxy, aryl, cyano, nitro, Het3, R6or NR7R8; R6is substituted sulfonyl or sulfinyl; R7and R8are hydrogen, optionally substituted C1-4alkyl, aryl, a carbonyl or thiocarbonyl linked substituent, C3-7cycloalkyl, Het3and R6; R9and R10are each independently selected from hydrogen, optionally substituted C1-4alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C3-7cycloalkyl, Het3and R6; R11is hydroxy, mercapto, cyano, nitro, halo, trihalomethyl, C1-4alkyloxy, carboxyl, C1-4alkyloxycarbonyl, trihaloC1-4alkylsulfonyloxy, R6, NR7R8, C(═O)NR7R8, aryl, aryloxy, arylcarbonyl, C3-7cycloalkyl, C3-7cycloalkyloxy, phthalimide-2-yl, Het3and C(═O)Het3; R12and R13are each independently selected from hydrogen, optionally substituted C1-4alkyl, phenyl, a carbonyl or thiocarbonyl linked substituent, C3-7cycloalkyl and R6; aryl is optionally substituted phenyl; Het1, Het2and Het3are optionally substituted heterocycles; to processes for their preparation and compositions comprising them. It further relates to their use as a medicine.

REFERENCES:
patent: 3883528 (1975-05-01), Mylari
patent: 3912723 (1975-10-01), Miller
patent: 4631278 (1986-12-01), Boeckx et al.
patent: 4767760 (1988-08-01), Boeckx et al.
patent: 5256631 (1993-10-01), Lindner et al.
patent: 2 149 645 (1972-09-01), None
patent: 0 170 316 (1986-02-01), None
patent: 0 232 932 (1987-08-01), None
patent: 0 476 439 (1992-03-01), None
patent: 0 648 760 (1995-04-01), None
patent: 0831088 (1998-03-01), None
Mishra et al. Journal of Immunology, 2464-2469, 2002.*
Baggiolini, et al., “CC Chemokines in Allergic Inflammation.”Immunology Today, 1994, pp. 127-133, vol. 15, No. 3.
Carr et al., “Expression On Porcine y δ lymphocytes Of A Phytogenetically Conserved Surface Antigen Previously Restricted in Expression y δ T Lymphocytes.”Immunology, 1994, pp. 36-40, vol.81.
Minnicozzi, M., “The Inhibition of Interleukin 5 in allergic diseases.”Expert Opinion on Therapeutic Patents, 1999, pp. 148-156, vol. 9(2).
PCT International Search Report for PCT Appln. No. PCT/EP 98/04191, mailed Nov. 17, 1998, which relates to this corresponding U.S. Application, filed herewith.

Affiliated with

Also associated with

Rating

IL-5 inhibiting 6-azauracil derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-5 inhibiting 6-azauracil derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-5 inhibiting 6-azauracil derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3414830